Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionCIBC Private Wealth Group, LLC
Latest Disclosed Ownership183 shares
Latest Disclosed Value $ 34,600
CIBC Private Wealth Group, LLC reports 22.82% increase in ownership of LGND / Ligand Pharmaceuticals Incorporated

On February 12, 2026 - CIBC Private Wealth Group, LLC filed a 13F-HR form disclosing ownership of 183 shares of Ligand Pharmaceuticals Incorporated (US:LGND) valued at $34,600 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 24, 2025 disclosing 149 shares of Ligand Pharmaceuticals Incorporated. This represents a change in shares of 22.82% during the quarter. The current value of the position is $43,371 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-12 2025-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 183 34 22.82 35 30.77 0.0001
2025-11-24 2025-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 149 69 86.25 26 188.89 0.0000
2025-08-12 2025-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 80 -123 -60.59 9 -52.63 0.0000
2025-05-14 2025-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 203 43 26.88 20 11.76 0.0000
2025-02-12 2024-12-31 13F Ligand Pharmaceuticals COM NEW 53220K504 160 0 0.00 18 6.25 0.0000
2024-11-13 2024-09-30 13F Ligand Pharmaceuticals COM NEW 53220K504 160 0 0.00 16 23.08 0.0000
2024-08-09 2024-06-30 13F Ligand Pharmaceuticals COM NEW 53220K504 160 0 0.00 14 18.18 0.0000
2024-05-10 2024-03-31 13F Ligand Pharmaceuticals COM NEW 53220K504 160 160 12 0.0000
2023-06-01 2022-12-31 13F/A-2 LIGAND PHARMACEUTICALS INC COM COM 53220K504 0 -12,041 -100.00 0 -100.00
2023-02-14 2022-12-31 13F/A-1 LIGAND PHARMACEUTICALS INC COM COM 53220K504 0 -12,041 0
2023-02-13 2022-12-31 13F LIGAND PHARMACEUTICALS INC COM COM 53220K504 0 -12,041 0
2022-11-15 2022-09-30 13F LIGAND PHARMACEUTICALS INC COM COM 53220K504 12,041 0 0.00 1,036 -3.54 0.0028
2022-08-03 2022-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 12,041 0 0.00 1,074 -20.74 0.0028
2022-05-16 2022-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 12,041 -17 -0.14 1,355 -27.23 0.0030
2022-04-04 2021-12-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 12,058 -116 -0.95 1,862 9.79 0.0039
2022-02-08 2021-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 12,058 -116 1,862 0.0030
2021-11-12 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 12,174 -1,929 -13.68 1,696 -8.32 0.0039
2021-08-16 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 14,103 -30 -0.21 1,850 -14.11 0.0042
2021-05-12 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 14,133 964 7.32 2,154 64.43 0.0054
2021-02-12 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 13,169 -1,820 -12.14 1,310 -8.33 0.0035
2020-11-03 2020-09-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 14,989 22 0.15 1,429 -14.64 0.0044
2020-08-13 2020-06-30 13F LIGAND PHARMACEUTICALS INC COM Com 53220K504 14,967 -4,571 -23.40 1,674 17.80 0.0081
2020-05-15 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 19,538 -2,822 -12.62 1,421 -39.04 0.0061
2020-01-30 2019-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 22,360 -46,793 -67.67 2,331 -66.13 0.0076
2019-10-16 2019-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 69,153 -3,523 -4.85 6,883 -17.02 0.0242
2019-07-31 2019-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 72,676 -4,058 -5.29 8,295 -14.01 0.0291
2019-05-10 2019-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 76,734 7,634 11.05 9,647 2.88 0.0372
2019-02-05 2018-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 69,100 8,823 14.64 9,377 -43.32 0.0418
2018-11-14 2018-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 60,277 -9,775 -13.95 16,544 14.00 0.0627
2018-08-02 2018-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 70,052 -77,933 -52.66 14,512 -40.62 0.0592
2018-05-17 2018-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 147,985 1,153 0.79 24,441 21.56 0.1062
2018-02-12 2017-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 146,832 2,993 2.08 20,106 2.66 0.0853
2017-12-21 2017-09-30 13F/A-1 LIGAND PHARMACEUTICALS INC COM COM NEW 53220K504 143,839 2,540 1.80 19,585 14.17 0.0893
2017-11-14 2017-09-30 13F LIGAND PHARMACEUTICALS INC COM COM NEW 53220K504 143,839 2,540 19,585
2017-08-09 2017-06-30 13F LIGAND PHARMACEUTICALS INC COM Com 53220K504 141,299 -1,094 -0.77 17,154 13.82 0.1077
2017-05-10 2017-03-31 13F LIGAND PHARMACEUTICALS INC COM Com 53220K504 142,393 -1,178 -0.82 15,071 3.32 0.0947
2017-02-13 2016-12-31 13F LIGAND PHARMACEUTICALS INC COM Com 53220K504 143,571 247 0.17 14,587 -0.27 0.0964
2016-11-09 2016-09-30 13F LIGAND PHARMACEUTICALS INC COM Com 53220K504 143,324 -24,561 -14.63 14,627 -26.95 0.1014
2016-08-11 2016-06-30 13F LIGAND PHARMACEUTICALS INC COM Com 53220K504 167,885 167,885 20,024 0.1462
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.